Anne Kristine Anstensrud

Publication Activity (10 Years)

Years Active: 2019-2024
Publications (10 Years): 4

Top Topics

Percutaneous Coronary Intervention

Juvenile Idiopathic Arthritis

Disease Activity

Top Venues

International journal of molecular sciences

This page only lists publications with an associated author ORCID identifier.

Publications

Fredric A Holme, Camilla Huse, Xiang Yi Kong, Kaspar Broch, Lars Lysgaard Gullestad, Anne Kristine Anstensrud, Geir Ø Andersen, Brage H Amundsen, Ola Kleveland, Ana Quiles-Jiménez, Sverre Holm, Pål Aukrust, Ingrun Alseth, Bente Halvorsen, Tuva Børresdatter Dahl
Circular RNA Profile in Atherosclerotic Disease: Regulation during ST-Elevated Myocardial Infarction. International journal of molecular sciences 25 (16) (2024)
Fredric A Holme, Camilla Huse, Xiang Yi Kong, Kaspar Broch, Lars Lysgaard Gullestad, Anne Kristine Anstensrud, Geir Ø Andersen, Brage H Amundsen, Ola Kleveland, Ana Quiles-Jiménez, Sverre Holm, Pål Aukrust, Ingrun Alseth, Bente Halvorsen, Tuva Børresdatter Dahl
Circular RNA Profile in Atherosclerotic Disease: Regulation during ST-Elevated Myocardial Infarction. International journal of molecular sciences 25 (16) (2024)
Sindre Woxholt, T Ueland, Pål Aukrust, Anne Kristine Anstensrud, Kaspar Broch, Ingvild Maria Tøllefsen, Liv Ryan, Bjørn Bendz, Einar Hopp, Nils-Einar Kløw, Ingebjørg Seljeflot, Bente Halvorsen, Tuva B Dahl, Camilla Huse, Geir Øystein Andersen, Lars Gullestad, Rune Wiseth, Brage H Amundsen, Jan Kristian Damas, Ola Kleveland
Cytokine pattern in patients with ST-elevation myocardial infarction treated with the interleukin-6 receptor antagonist tocilizumab. Open heart 10 (2) (2023)
Anne Kristine Anstensrud, Sindre Woxholt, Kapil Sharma, Kaspar Broch, Bjørn Bendz, Svend Aakhus, Thor Ueland, Brage H Amundsen, Jan Kristian Damås, Einar Hopp, Ola Kleveland, Knut Haakon Stensæth, Anders Opdahl, Nils-Einar Kløw, Ingebjørg Seljeflot, Geir Øystein Andersen, Rune Wiseth, Pål Aukrust, Lars Gullestad
Rationale for the ASSAIL-MI-trial: a randomised controlled trial designed to assess the effect of tocilizumab on myocardial salvage in patients with acute ST-elevation myocardial infarction (STEMI). Open heart 6 (2) (2019)